MASCC Score Calculation and Interpretation for Febrile Neutropenia Risk Stratification
The MASCC (Multinational Association for Supportive Care in Cancer) score is calculated by summing weighted points across seven clinical variables present at fever onset, with a score ≥21 identifying low-risk patients who have only 1% mortality and 6% serious complication rates, making them candidates for less intensive management including potential outpatient oral antibiotic therapy. 1
Score Calculation Components
The MASCC scoring system assigns points based on the following characteristics at presentation 1:
Burden of illness:
- No or mild symptoms: 5 points
- Moderate symptoms: 3 points
- Severe symptoms: 0 points
- (Note: These points are NOT cumulative—only one category applies)
No hypotension (systolic BP >90 mmHg): 5 points 1
No chronic obstructive pulmonary disease: 4 points 1
Solid tumor or lymphoma with no previous fungal infection: 4 points 1
No dehydration: 3 points 1
Outpatient status at onset of fever: 3 points 1
Age <60 years: 2 points 1
The maximum theoretical score is 26 points 1.
Risk Stratification Interpretation
Low-risk patients (MASCC score ≥21) have:
- Serious medical complication rate of approximately 6% 1
- Mortality rate of only 1% 1
- 98.3% likelihood of recovering without complications 2
High-risk patients (MASCC score <21) have:
- Serious medical complication rate of 50% 2
- Mortality rate of 36.4% 2
- Significantly higher rates of sepsis-related death 2
Clinical Application and Performance
The MASCC score demonstrates excellent predictive accuracy with sensitivity of 78.8-100%, specificity of 60-85%, positive predictive value of 86-98.3%, and negative predictive value of 80.9-86.4% across multiple validation studies 2, 3, 4, 5.
Management Implications Based on Risk Stratification:
For low-risk patients (≥21):
- Consider outpatient oral antibiotic therapy as a safe alternative to intravenous treatment 1
- Patients must be hemodynamically stable, without acute leukemia, organ failure, pneumonia, indwelling venous catheter, or severe soft tissue infection 1
- Only 1.9% mortality risk in this group 4
For high-risk patients (<21):
- Require hospitalization with intravenous broad-spectrum antibiotics 1
- 9-43.3% develop serious complications requiring intensive monitoring 4, 6
- May benefit from early ICU-level care consideration 6
Important Clinical Caveats
The MASCC score should be calculated rapidly before neutrophil count results are available and does not require knowledge of underlying cancer burden, making it practical for emergency department use 1.
Critical pitfall: Even in low-risk patients, 7-12.5% may still develop complications 3, 4. Patients with complex infections (such as those with indwelling catheters or documented bacteremia) may be misclassified as low-risk and should be managed more conservatively 7.
The score performs best in cycle 1 of chemotherapy, where 59% of febrile neutropenia events occur, with decreasing incidence in subsequent cycles 8.
Despite guideline recommendations, the MASCC score remains underutilized in clinical practice—only 2% of hospitalized patients had documented MASCC scores in one study, representing a significant opportunity to improve care and reduce unnecessary hospitalizations 6, 9.